Business
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is
About this update from Beyond Air, Inc.
[{"type":"text","content":"GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the first patient was treated in a first-in-human Phase 1 study to assess the safety and immune biomarkers of UNO therapy. Ido Wolf, M.D., Head, Oncology Division, Tel Aviv Sourasky Medical Center, Professor of Oncology, Faculty of Medicine, Tel Aviv University, Head, National Israeli Council for Prevention, Diagnosis and Treatment of Malignant Diseases, commented, “UNO therapy is very promising given the local delivery and surprising speed and ease of administration. I am looking forward to completing this Phase I study and assessing the potential for efficacy.” “We are proud to announce today the important milestone of advancing our UNO therapy into the clinic,” commented Selena Chaisson, CEO of Beyond Cancer. “This is a critical step in our mission to provide cancer patients a therapeutic option that may prevent metastases and end relapse. We anticipate initial clinical data from this trial in early 2023.” Jedidiah Monson, M.D., Chief Medical Officer of Beyond Cancer, added, “This open-label, first-in-human, single administration, Phase I study is a promising advancement as a new approach towards treating solid tumors with nitric oxide. The study will evaluate the maximum tolerated dose (MTD), safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment.” \"Once again the Beyond Air team executes, this time in collaboration with our Beyond Cancer colleagues. The team’s tireless efforts over the past three years have led us to this day,” stated Steve Lisi, Chairman and CEO of Beyond Air and Chairman of Beyond Cancer. “We will continue our rapid development to determine what role UNO therapy may play in the fight against solid tumors.” The primary endpoints of the Phase 1 study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities, and changes in safety parameters. The dose for future studies will be determined based on the MTD with additional consideration for all available safety and biomarker data. The secondary endpoints include standard effic...